bharat-biotech-launches-oral-cholera-vaccine-hillchol

Bharat Biotech launches oral cholera vaccine Hillchol

Bharat Biotech launched Hillchol, a single-strain oral cholera vaccine, developed under licence from Hilleman Laboratories. With global demand for oral cholera vaccines exceeding 100 million doses annually, Bharat Biotech's Hyderabad and Bhubaneswar facilities can produce up to 200 million doses, addressing the global vaccine shortage.

News Arena Network - Hyderabad - UPDATED: August 27, 2024, 01:46 PM - 2 min read

Bharat Biotech launches oral cholera vaccine Hillchol

Bharat Biotech International Ltd has launched its oral cholera vaccine (OCV) Hillchol.

Bharat Biotech International Ltd (BBIL) announced on Tuesday the launch of Hillchol, a new single-strain oral cholera vaccine.

Hillchol (BBV131) was developed by Bharat Biotech under a licence from Hilleman Laboratories, funded by Merck USA and the Wellcome Trust, to combat cholera. Global demand for oral cholera vaccines (OCVs) exceeds 100 million doses annually, making them vital for cholera control.

Currently, there is only one manufacturer meeting this demand, leading to a global shortage.

BBIL has established large-scale manufacturing facilities in Hyderabad and Bhubaneswar, capable of producing up to 200 million doses of Hillchol annually.

The vaccine underwent a multi-stage clinical evaluation process, culminating in a phase 3 study that confirmed its safety, immunogenicity, and non-inferiority to existing OCVs.

The vaccine is administered orally in a single dose on days 0 and 14 and is suitable for individuals aged over one year.

Related Tags: